The Medical Advisor

For more than two decades, hormone therapy for menopause was widely viewed as dangerous. Millions of women were discouraged from using estrogen or combined hormone replacement therapy (HRT), often being told the risks outweighed any potential benefit. In 2025, the U.S. Food and Drug Administration (FDA) made a landmark decision: it removed the long-standing black box warning from hormone-based menopause drugs. The move has reignited debate over whether a generation of women was misled about hormone therapy — and how menopause treatment should be approached today.   The Women’s Health Initiative and the Rise of Hormone Therapy Fear The shift in public perception began in 2002 with early findings from the Women’s Health Initiative (WHI), a large U.S. government-funded study examining hormone replacement therapy in postmenopausal women. Initial headlines warned that hormone therapy increased the risk of: Breast cancer Heart attacks Stroke and blood clots Dementia Pres...

Introduction Cancer care is evolving beyond a narrow focus on tumor destruction toward a more comprehensive model that considers metabolism, immunity, inflammation, and quality of life. Within this broader framework, nutritional pharmacology—the use of nutrients at pharmacological doses to influence biological pathways—has gained renewed interest. Proponents argue that certain nutrients, when administered at doses far exceeding dietary intake, may exert effects comparable to drugs: modulating oxidative stress, immune function, angiogenesis, and tumor metabolism. Critics counter that enthusiasm has outpaced evidence. The truth likely lies between these positions. This article examines the scientific rationale, clinical evidence, and limitations of nutritional pharmacology in cancer care, with particular attention to high-dose intravenous vitamin C , the most extensively studied example. What Is Nutritional Pharmacology? Nutritional pharmacology differs fundamentally from conventiona...

Brain cancer, particularly aggressive forms like glioblastoma multiforme (GBM), remains one of the most formidable challenges in oncology, with limited treatment options, high recurrence rates, and dismal survival prognoses despite advances in surgery, chemotherapy, and radiation.  In recent years, however, a paradigm shift has emerged through the repurposing of established antiparasitic medications—ivermectin and mebendazole—as potential adjunctive therapies. These drugs, long proven safe for human use against parasitic infections, are now drawing attention for their anticancer properties, including the ability to target cancer stem cells, disrupt tumor metabolism, and cross the blood-brain barrier to combat intracranial malignancies.  Drawing from a surge of compelling success stories documented from 2019 (METRICS study) to 2025, this article explores more than 100 real-world case reports of patients achieving remarkable outcomes, such as tumor stabilization, shrinkage, and ...